Transaction in Own Shares

 
TIDMNVOB 
 
Novo Nordisk A/S - Share repurchase programme 
 
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in 
accordance with the provisions of the European Commission's regulation no 
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. 
 
Under the programme Novo Nordisk will repurchase B shares for an amount up to 
DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010. 
 
 
Since the announcement as of 15 February 2010, the following transactions have 
been made under the programme: 
 
                        Number of shares Average purchase  Transaction value, 
                                               price                       DKK 
 
 Accumulated, last               885,000                            331,984,754 
 announcement 
 
 15 February 2010                 75,000          391.0200           29,326,500 
 
 16 February 2010                 90,000          391.3800           35,224,200 
 
 17 February 2010                 90,000          392.8600           35,357,400 
 
 18 February 2010                 75,000          393.4850           29,511,375 
 
 19 February 2010                 90,000          394.1670           35,475,030 
 
 Accumulated under the         1,305,000                            496,879,259 
 programme 
 
 
Transactions related to Novo Nordisk's incentive programmes have resulted in a 
net sale by Novo Nordisk of 125,650 B shares in the period from 15 February 
2010 to 19 February 2010. The shares in these transactions were not part of the 
Safe Harbour repurchase programme. 
 
With the transactions stated above, Novo Nordisk owns a total of 31,576,298 
treasury shares, corresponding to 5.1% of the share capital. The total amount of 
shares in the company is 620,000,000 including treasury shares. 
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. In 
addition, Novo Nordisk has a leading position within areas such as haemostasis 
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk 
manufactures and markets pharmaceutical products and services that make a 
significant difference to patients, the medical profession and society. With 
headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 
countries, and markets its products in 179 countries. Novo Nordisk's B shares 
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed 
on the New York Stock Exchange under the symbol 'NVO'. For more information, 
visit novonordisk.com. 
 
Further information: 
 
 
 Media:                                  Investors: 
 
 
 Mette Kruse Danielsen                   Klaus Bülow Davidsen 
 
 Tel: [phone]                    Tel: [phone] 
 
 [e-mail]                     [e-mail] 
 <mailto:[e-mail]>            <mailto:[e-mail]> 
 
 
                                         Kasper Roseeuw Poulsen 
 
                                         Tel: [phone] 
 
                                         [e-mail] 
                                         <mailto:[e-mail]> 
 
 
 In North America:                       In North America: 
 
 Sean Clements                           Hans Rommer 
 
 Tel: [phone]                  Tel: [phone] 
 
 [e-mail]                    [e-mail] 
 <mailto:[e-mail]>           <mailto:[e-mail]> 
 
 
Company Announcement no 10 / 2010 
 
 
 
 
 
[HUG#1387085] 
 
 
 
 
 
    Company Announcement no 10 2010: http://hugin.info/2013/R/1387085/345487.pdf